Read our new blog post on the importance of due diligence – click for more details       Read our new blog post on the importance of due diligence – click for more details        Read our new blog post on the importance of due diligence – click for more details        Read our new blog post on the importance of due diligence – click for more details       
CONTACT US
May 2026

The Future of Ethanol in Pharmaceuticals: Sustainability and Supply Chain Resilience

Written by:

Jamie Pringle

Ethanol is one of the most widely used excipients in the pharmaceutical industry. Its role as a solvent, preservative and processing aid makes it indispensable across a broad spectrum of formulations and manufacturing processes. As demand grows — and as global supply chains face new pressures — the future of pharmaceutical ethanol will be defined by two priorities: sustainability and resilience.

Sustainability: Reducing Environmental Footprint

Ethanol’s renewable origin, typically from fermentation of agricultural feedstocks, already positions it more sustainably than many synthetic excipients. However, regulators, manufacturers and patients are demanding more:

  • Decarbonisation of feedstocks: Increased use of low-carbon agricultural inputs, waste biomass, or second-generation sources (e.g., cellulosic ethanol)
  • Energy efficiency in production: Adoption of advanced distillation and dehydration technologies to reduce energy consumption
  • Waste minimisation: Circular use of by-products, such as animal feed or bioenergy recovery from fermentation residues
  • Certification schemes: Standards, such as B Corp & EcoVadis, provide frameworks for demonstrating ethanol’s sustainability credentials

Supply Chain Resilience: Ensuring Continuity of Supply

The COVID-19 pandemic underscored the vulnerability of global ethanol supply chains, as pharmaceutical users competed with surging demand from sanitiser and industrial markets. Looking ahead, resilience will require:

  • Diversified sourcing strategies: Reducing reliance on single geographies by building regional supply networks
  • Stockholding and safety buffers: Maintaining strategic reserves of GMP-certified ethanol to mitigate disruptions
  • Digital traceability: Blockchain and advanced ERP systems enabling end-to-end visibility of feedstock origin, processing, and certification
  • Supplier partnerships: Closer collaboration throughout the supply chain to align production capacity with pharmaceutical-grade demand

Regulatory and Market Drivers

Sustainability and resilience are not optional add-ons — they are increasingly mandated:

  • Regulators expect risk-based supply chain mapping under ICH Q9 (Quality Risk Management)
  • Pharmaceutical companies are embedding Scope 3 carbon reduction targets into procurement strategies
  • End users — patients and healthcare systems — are placing greater value on sustainable and ethically sourced medicines

Ethanol’s role in pharmaceuticals is secure, but its future license to operate depends on more than quality and compliance. The next decade will see GMP-certified ethanol defined not only by purity and regulatory conformity but also by its sustainability credentials and the resilience of its supply chains.

For excipient suppliers and pharmaceutical manufacturers alike, investing in these areas today is essential to ensure that ethanol continues to be a trusted, compliant and future-ready excipient in global healthcare.

Managing ethanol supply means more than arranging transport. It requires a proactive approach to risk, regulation and relationships. At Kimia, we combine diversified sourcing, global logistics expertise and strict EXCiPACT-GMP compliance to deliver products that are not only safe and compliant, but also future-ready.

Discover how Kimia supports sustainable, resilient ethanol supply for pharmaceuticals here.

Read Previous Read Next